William Blair analyst Brandon Vazquez has maintained their bullish stance on PRCT stock, giving a Buy rating on February 23.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Brandon Vazquez has given his Buy rating due to a combination of factors that, in his view, are not reflected in the current share price. Despite the recent 30% decline driven by an inventory reset and commercial realignment, he sees these as temporary execution issues rather than signs of a fundamental problem with Aquablation or the company’s long‑term opportunity.
He highlights that Aquablation is backed by multiple randomized clinical trials, solid reimbursement, and consistent underlying procedure growth, supporting its positioning in the benign prostatic hyperplasia market. With the stock now trading near 2x his updated 2026 sales estimate, he believes valuation is at the low end versus comparable medtech names, while upside from an underpenetrated market, potential expansion into prostate cancer, and experienced leadership remains largely unrecognized.
In another report released on February 23, TD Cowen also reiterated a Buy rating on the stock with a $50.00 price target.